Remifentanil as an alternative to epidural analgesia for vaginal delivery

Primary tabs

SCIENCE
Remifentanil as an alternative to epidural analgesia for vaginal delivery
Key Take-Away: 

Remifentanil PCA (R-PCA) significantly improves patient’s outcomes in peripartum period and exhibits similar efficacy as epidural analgesics in the management of labor pain.

Epidural analgesics are the most promising and effective medication for labor pain management. 

ABSTRACT: 
Background: 

Epidural analgesics are the most promising and effective medication for labor pain management. Although epidural analgesia is considered the gold standard for labor pain management, its use may be restricted in some conditions due to clinical contraindications or availability, and suitable alternatives may be required.

The objective of this meta-analysis was to determine whether evidence from randomized trials suggests remifentanil PCA (R-PCA) results in significant differences in maternal satisfaction, analgesic efficacy, and safety compared with conventional epidural analgesia (EA).

Methods: 

A meta-analysis was conducted by systematically searching MEDLINE, EMBASE and Cochrane Library for all randomized controlled trials (RCTs) allocating parturients to R-PCA or EA and reporting at least one outcome of interest. Eight randomized trials of R-PCA vs. EA with 2351 patients were included.

The primary outcome of interest was maternal satisfaction. While the secondary outcomes was visual analog pain score (VAS at 1, 2, 3 h postoperatively), nausea, vomiting, pruritus, hypoxemia, acute respiratory depression or death (maternal or neonatal), need for Cesarean section, and neonatal Apgar score.

Results: 

Meta-analysis of the randomized trials showed no significant differences between the R-PCA and EA groups for maternal satisfaction, VAS at 2 or 3 h, nausea, vomiting, need for cesarean section, respiratory depression, umbilical pH, and neonatal Apgar score at 1 min and 5 min.

However, the incidence of hypoxemia was higher [OR 7.48, 95%CI 3.42–16.36] and VAS at 1 h was slightly higher [WMD 1.33, 95%CI 0.30–2.36] with R-PCA versus EA. Pruritus was less frequent in the R-PCA group [OR 0.54, 95%CI 0.32–0.89]. Acute respiratory failure and death were not reported in any of the studies.

Conclusion: 

While no significant differences were detected for maternal satisfaction or most clinical outcomes, this meta-analysis remains underpowered to rule out clinically-important differences due to the few existing randomized trials.

For patients who are not candidates for EA, R-PCA may provide an alternative for analgesia in the peripartum period, but caution is warranted particularly regarding hypoxemia and suggests the need for increased surveillance and monitoring for R-PCA. Further, adequately powered randomized trials with a focus on clinically-relevant maternal and neonatal outcomes are required to more accurately characterize the relative benefits and risks of R-PCA versus EA in this population.

Source:

Journal of Clinical Anesthesia

Link to the source:

http://www.jcafulltextonline.com/article/S0952-8180(17)30335-5/fulltext?rss=yes

The original title of the article:

Remifentanil as an alternative to epidural analgesia for vaginal delivery: A meta-analysis of randomized trials

Authors:

Myeongjong Lee et al.

Log in or register to post comments